Post-menopausal patients with ER+ and HER2- primary breast cancer Cancer
Conditions
Interventions
1. Palbociclib is an unlicensed drug that is a 125-mg capsule that should be administered orally. The treatment schedule is 3 weeks on, 1 week off.
2. Letrozole is a 2.5-mg tablet that will be admini
Sponsors
The Institute for Cancer Research
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Postmenopausal women defined as: 1.1. Age 56 or older with no spontaneous menses for at least 12 months prior to study entry 1.2. Age 55 or younger with no menses for at least 12 months prior to study entry (e.g., spontaneous or secondary to hysterectomy) and with a documented oestradiol level in the postmenopausal range according to local institutional/laboratory standard 1.3. Age =16 with documented bilateral oophorectomy 2. Operable ER+ HER2- invasive early breast cancer suitable for neoadjuvant AI treatment. ER positivity is defined as an Allred score of 3 (or equivalent) [sentence added 01/11/2016]. HER2 negativity will be defined as per the 2013 ASCO/CAP guidelines as follows: 2.1. IHC 1+ as defined by incomplete membrane staining that is faint/barely perceptible and within >10% of the invasive tumour cells 2.2. IHC 0 as defined by no staining observed or membrane staining that is incomplete and is faint/barely perceptible and within =10% of the invasive tumour cells 2.3. ISH negative based on: 2.3.1. Single-probe average HER2 copy number 1.5 x 109/L) 7.3. Platelets = 100,000/mm³ (> 100 x 109/L) 7.4. AST and/or ALT 1.5 x upper normal limits (ULN) 7.5 Alkaline phosphatase 1.5 x ULN 7.6. Total serum bilirubin ULN unless the patient has a bilirubin elevation > ULN to 1.5 x ULN due to Gilbert's disease or similar syndrome involving slow conjugation of bilirubin 7.7. Serum creatinine = 1.25 x ULN or estimated creatinine clearance < 60 mL/min (as calculated using the method standard for the institution) 7.8. No severe and relevant co-morbidity that would affect a patient?s participation in the study 7.9. INR must be within normal limits of the local laboratory ranges 8. Written informed consent to participate in the trial and to donation of tissue and blood samples 9. Patients must have the ability to swallow oral medication
Exclusion criteria
Exclusion criteria: 1. Premenopausal or perimenopausal women 2. Inflammatory/inoperable breast cancer 3. HER2 positive 4. Concurrent use (defined as use within 4 weeks prior to baseline tissue sample being taken) of HRT or any other oestrogen-containing medication (including vaginal oestrogens) 5. Prior endocrine therapy for breast cancer 6. Any invasive malignancy within previous 5 years (other than basal cell carcinoma or cervical carcinoma in situ) 7. Bilateral invasive disease (added 01/11/2016) 8. Any severe coincident medical disease, including seizure disorder requiring medication 9. Diagnosis by FNA alone or excisional biopsy or lumpectomy performed prior to study entry 10. Surgical axillary staging procedure prior to study procedure (with the exception of FNA or core biopsy) 11. Definitive clinical or radiologic evidence of metastatic disease 12. History of ipsilateral invasive breast cancer regardless of treatment or ipsilateral DCIS treated with radiotherapy or contralateral invasive breast cancer at any time 13. New York Hearth Association classification of level III or IV heart disease 14. Any treatment, including radiotherapy, chemotherapy, and/or targeted therapy, administered for the currently diagnosed breast cancer prior to study entry 15. Patients on established CYP3A inhibitors/inducers 16. QTc >480 msec or a family or personal history of long or short QT syndrome, Brugada syndrome or know history of QTc prolongation, or Torsade de Pointes (TdP) 17. Active Hepatitis B or Hepatitis C with abnormal liver function tests 18. HIV positive patients receiving antivirals
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1. Change in the proliferation marker Ki67 (% positive tumour cells) as tested by IHC from baseline to after 14 weeks treatment with letrozole with or without palbociclib 2. Clinical response as measured by ultrasound according to ECOG criteria after 14 weeks treatment with letrozole with or without palbociclib | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Effect of palbociclib on Ki67 after 2 weeks and the added effect of letrozole from weeks 2-14 (within group) 2. Effect of letrozole on Ki67 after 2 weeks and the added effect of palbociclib from weeks 2-14 (within group) 3. pCR rates after letrozole with or without 14 weeks palbociclib 4. PEPI score after letrozole with or without 14 weeks palbociclib 5. Assessment of safety and tolerability 6. Changes between surgical intent at baseline, surgical intent after 14 weeks and actual surgery received after treatment with letrozole with or without palbociclib (added 01/11/2016) | — |
Countries
England, United Kingdom
Outcome results
None listed